# Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/talazoparib-plus-enzalutamide-in-men-with-first-line-metastatic-castration/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Neeraj Agarwal,Arun Azad,Joan Carles,André P. Fay,Nobuaki Matsubara,Daniel Heinrich,Cezary Szczylik,Ugo De Giorgi,Jae Young Joung,Peter C.C. Fong,Éric Voog,Robert J. Jones,Neal D. Shore,Curtis Dunshee,Stefanie Zschäbitz,Jan Oldenburg,Xun Lin,Cynthia G. Healy,Nicola Di Santo,Fabian Zohren,Karim Fizazi |
| Citations | 518 |
| DOI | 10.1016/s0140-6736(23)01055-3 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4379285544 |
| PMID | 37285865 |
| Type | article |
| Year | 2023 |

## Paper authors

- [Neeraj Agarwal](https://scholariq.org/researchers/neeraj-agarwal/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)

## Paper topics

- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.